(NASDAQ: GH) Guardant Health's forecast annual revenue growth rate of 25.67% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.49%.
Guardant Health's revenue in 2026 is $1,183,105,000.On average, 30 Wall Street analysts forecast GH's revenue for 2026 to be $182,640,987,370, with the lowest GH revenue forecast at $171,905,293,770, and the highest GH revenue forecast at $191,900,523,100. On average, 30 Wall Street analysts forecast GH's revenue for 2027 to be $240,076,948,130, with the lowest GH revenue forecast at $214,042,891,150, and the highest GH revenue forecast at $268,794,928,510.
In 2028, GH is forecast to generate $319,521,080,770 in revenue, with the lowest revenue forecast at $265,708,416,600 and the highest revenue forecast at $392,523,797,250.